Presentation is loading. Please wait.

Presentation is loading. Please wait.

PLK1 is a crucial downstream effector of PDK1 for MYC activation and cell survival. PLK1 is a crucial downstream effector of PDK1 for MYC activation and.

Published byAubrie Lee Modified over 4 years ago

Similar presentations

Presentation on theme: "PLK1 is a crucial downstream effector of PDK1 for MYC activation and cell survival. PLK1 is a crucial downstream effector of PDK1 for MYC activation and."— Presentation transcript:

1 PLK1 is a crucial downstream effector of PDK1 for MYC activation and cell survival.
PLK1 is a crucial downstream effector of PDK1 for MYC activation and cell survival. A, cell viability of HEK-vector, HEK-PDK1, and HEK-E545K cells treated with the indicated concentrations of BI2536 and GW843682X for 4 days. B, cell viability of RWPE-1 and HMEC-derived cell lines treated with 10 nmol/L BI2536 for 4 days. C, immunoblot analysis of PLK1 in indicated cell lines. D, soft-agar growth of indicated cell lines treated with 10 nmol/L BI2536 for 14 days. E, immunoblot analysis in HEK-PDK1 and -MYC cells treated with BI2536 and GW843682X at indicated concentration for 24 hours. F, apoptosis by sub-G1 analysis of indicated cell lines treated with 10 nmol/L BI2536 for 48 hours. G, apoptosis of indicated cell lines treated with NC or PLK1 siRNAs for 48 hours (top) and immunoblot analysis of indicated proteins (bottom). H, xenograft tumor growth of HEK-PDK1 and HEK-E545K cells in nude mice treated with 50 mg/kg BI2536 twice per week as described in Methods. Data are mean ± SEM (n = 5 for each group). I, cell viability assay showing the dose response of a panel of breast cancer cell lines that are MYC-dependent (MDA-MB-231, SUM159PT, and Hs578T) and -independent (T47D, BT474, MCF-10A, and HMEC) to BI2536 treatment. Jing Tan et al. Cancer Discovery 2013;3: ©2013 by American Association for Cancer Research

Download ppt "PLK1 is a crucial downstream effector of PDK1 for MYC activation and cell survival. PLK1 is a crucial downstream effector of PDK1 for MYC activation and."

Similar presentations

A Novel Cinnamide YLT26 Induces Breast Cancer Cells Apoptosis via ROS-Mitochondrial Apoptotic Pathway in Vitro and Inhibits.

A Novel Cinnamide YLT26 Induces Breast Cancer Cells Apoptosis via ROS-Mitochondrial Apoptotic Pathway in Vitro and Inhibits.
Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in.

Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in.
CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.

CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.
Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.
Combined inhibition of MAP kinase and KIT signaling destabilizes ETV1 protein and results in enhanced growth suppression of human GIST cells. Combined.

Combined inhibition of MAP kinase and KIT signaling destabilizes ETV1 protein and results in enhanced growth suppression of human GIST cells. Combined.
Cytotoxic therapy induces macrophage recruitment, as well as CSF1 and IL-34 mRNA expression. Cytotoxic therapy induces macrophage recruitment, as well.

Cytotoxic therapy induces macrophage recruitment, as well as CSF1 and IL-34 mRNA expression. Cytotoxic therapy induces macrophage recruitment, as well.
Volume 18, Issue 1, Pages (July 2010)

Volume 18, Issue 1, Pages (July 2010)
BV6 increases tumor burden in bone.

BV6 increases tumor burden in bone.
NRP2 represses IGF-IR expression and signaling.

NRP2 represses IGF-IR expression and signaling.
DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.

DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.
PDK1 regulates PLK1 in vivo and in vitro.

PDK1 regulates PLK1 in vivo and in vitro.
Level of EGFR inhibition determines cell death response in EGFR mutant GBM cells. Level of EGFR inhibition determines cell death response in EGFR mutant.

Level of EGFR inhibition determines cell death response in EGFR mutant GBM cells. Level of EGFR inhibition determines cell death response in EGFR mutant.
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
nab-Paclitaxel targets the tumor epithelial cells.

nab-Paclitaxel targets the tumor epithelial cells.
miR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NNK

miR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NNK
A, left: indicated MEFs were transfected as described in the Methods section. A, left: indicated MEFs were transfected as described in the Methods section.

A, left: indicated MEFs were transfected as described in the Methods section. A, left: indicated MEFs were transfected as described in the Methods section.
PI(3,4,5)P3 releases SIN1-PH–mediated inhibition on mTOR-KD, leading to mTORC2 activation. PI(3,4,5)P3 releases SIN1-PH–mediated inhibition on mTOR-KD,

PI(3,4,5)P3 releases SIN1-PH–mediated inhibition on mTOR-KD, leading to mTORC2 activation. PI(3,4,5)P3 releases SIN1-PH–mediated inhibition on mTOR-KD,
Imipramine and promethazine induce the apoptotic cell death of SCLC cells through activation of caspase-3. Imipramine and promethazine induce the apoptotic.

Imipramine and promethazine induce the apoptotic cell death of SCLC cells through activation of caspase-3. Imipramine and promethazine induce the apoptotic.
Volume 36, Issue 2, Pages (October 2009)

Volume 36, Issue 2, Pages (October 2009)
Role of HER2 in mediating acquired resistance to EGFR inhibition.

Role of HER2 in mediating acquired resistance to EGFR inhibition.

Similar presentations

Ads by Google